Form 4: Celularity Director Diamandis Receives RSU Grant

Celularity Inc. Director Peter Diamandis was granted 47,042 shares of Class A Common Stock as Restricted Stock Units under the company's 2021 Equity Incentive Plan.

Summary

• Peter Diamandis, a Director of Celularity Inc. (CELU), acquired 47,042 shares of Class A Common Stock.
• The acquisition occurred on November 19, 2025, and was reported on November 21, 2025.
• These shares represent Restricted Stock Units (RSUs) granted under the Celularity Inc. 2021 Equity Incentive Plan.
• Each RSU represents a right to receive one share of the Issuer's Class A common stock.
• The RSUs vested and became exercisable on the date of grant, with a transaction price of $0.00 per share.
• Following this transaction, Peter Diamandis beneficially owns 248,765 shares of Class A Common Stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it indicates continued insider ownership and alignment of interests, which is generally viewed favorably. However, it's a routine compensation event rather than a direct market purchase, limiting its impact on overall sentiment.

Positives

• The grant of Restricted Stock Units increases Peter Diamandis's beneficial ownership in Celularity Inc., aligning his interests with those of shareholders.
• The transaction reflects ongoing compensation and retention of a key director.

Future Outlook

This filing reports a routine equity grant as part of director compensation, which is a standard practice. It does not provide broader forward-looking statements or guidance regarding the company's operational or financial performance.

Industry Context

The grant of Restricted Stock Units to a director is a common form of non-cash compensation in the biotechnology and pharmaceutical industries, aiming to align management and director incentives with long-term shareholder value creation.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) for director compensation is a widely accepted practice across various industries, including biotech, aligning with global benchmarks for corporate governance and executive incentive structures.
• The $0.00 transaction price for RSUs is standard, as these are typically granted as part of a compensation package rather than purchased at market value.

Corporate Governance

Related Party Transactions

• Grant of 47,042 Restricted Stock Units to Peter Diamandis, a director of Celularity Inc., as compensation under the company's 2021 Equity Incentive Plan. This is a standard related-party transaction for director compensation.

Stakeholder Impact

• Shareholders: Increased alignment of director's interests with shareholder value through equity ownership.
• Employees: No direct impact on general employees mentioned in this filing.

Key Dates

Recommendation

This Form 4 reports a routine grant of Restricted Stock Units to a director as part of their compensation, which is a standard practice and does not provide new information to warrant a change in investment recommendation based solely on this filing. It is a non-event in terms of fundamental company performance or strategic direction.

Keywords

Celularity, CELU, Peter Diamandis, Form 4, Insider Transaction, Restricted Stock Units, RSU, Equity Grant, Director Compensation, 2021 Equity Incentive Plan